The commercial profile of Sanofi and Regeneron’s Dupixent continues to be strengthened; it is now approved  to treat adolescent patients (aged 12 to 17 years) in Europe.
The FDA approved similar labelling in March, which has resulted in an acceleration of US prescriptions. Little wonder as experts view Dupixent’s availability in younger patients as addressing an important unmet need; one of our previous snap polls predicted rapid adoption  in this cohort.
As a follow-up, we are snap-polling EU5 dermatologists to ascertain what impact this approval may have on their own use in the adolescent population…
Q. How would you best describe the level of unmet need for an effective treatment for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17?
Q. European approval of Dupixent (dupilumab) has now been expanded to include use in adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis that is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Approval is based on data from the LIBERTY AD programme, including a Phase III trial evaluating the efficacy and safety of Dupixent in adolescents with uncontrolled moderate-to-severe atopic dermatitis. Results from the studies showed that at 16 weeks, 42% of patients who received Dupixent achieved 75% or greater skin improvement compared to 8% with placebo, as measured by the Eczema Area and Severity Index (EASI-75). Meanwhile, 24% of those who received Dupixent achieved clear or almost clear skin compared to 2% with placebo, as measured by an Investigator's Global Assessment (IGA) score of 0 or 1.
The safety profile of Dupixent in the adolescent trial was similar to the safety profile from studies in adults with atopic dermatitis.
Based on these data what is your perception of Dupixent as a treatment option for adolescent patients with moderate-to-severe atopic dermatitis?
Q. Assuming you have access to Dupixent (dupilumab) how would you plan to use it for the treatment of adolescent patients with moderate-to-severe atopic dermatitis?
Q. How would you best describe your clinical experience with using Dupixent for the treatment of adult patients with moderate-to-severe atopic dermatitis?
Q. Do you agree that the opportunity for future oral treatments for moderate-to-severe atopic dermatitis (i.e. potentially JAK inhibitors, for example) will be higher in adolescent patients versus adult patients?
Neither agree nor disagree
Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here .
As always, FirstWord would very much like to receive your feedback and suggestions.
Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at firstname.lastname@example.org .
Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls. However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.